Neonatal lupus is a rare condition caused by the transfer of certain maternal antibodies across the placenta during pregnancy. It can affect the developing fetus or newborn, most notably causing a characteristic skin eruption or damage to the heart’s electrical conduction system. Blood-cell and liver abnormalities also occur. Despite its name, neonatal lupus is not the same disease as systemic lupus erythematosus in the infant. Most noncardiac manifestations disappear as maternal antibodies are cleared, whereas complete heart block is generally permanent.
Cause and mechanism
Neonatal lupus is associated primarily with maternal anti-Ro/SSA antibodies, often accompanied by anti-La/SSB antibodies. A small minority of cases, particularly those involving the skin, are associated with anti-U1-RNP antibodies.
These autoantibodies react with components of the body’s own cells. They belong mainly to the immunoglobulin G class, which normally crosses the placenta through a transport process involving the neonatal Fc receptor. Placental antibody transfer ordinarily provides passive protection against infection; in neonatal lupus, particular transferred autoantibodies can instead contribute to fetal tissue injury.
In the heart, antibody-associated inflammation can lead to fibrosis and injury of the atrioventricular conduction system. This system transmits electrical impulses from the upper to the lower chambers of the heart. Antibody exposure alone is insufficient to explain all cases: most exposed fetuses remain unaffected, indicating that additional fetal and maternal factors influence susceptibility.
The mother may have systemic lupus erythematosus, Sjögren syndrome, another autoimmune disease, or no recognized autoimmune illness. Maternal symptoms are therefore not necessary for neonatal lupus to occur. The condition is not contagious and does not represent straightforward inheritance of lupus.
Frequency and recurrence
Among pregnancies in women with anti-Ro/SSA antibodies and no previously affected child, the risk of congenital heart block is approximately 1–2%. After a pregnancy affected by cardiac neonatal lupus, the risk of cardiac involvement in a subsequent pregnancy rises to roughly 15–20%. These figures describe cardiac disease, not the combined frequency of all neonatal lupus manifestations.
Reported frequencies of skin, liver, and blood abnormalities vary with how infants are examined and followed. Mild or transient abnormalities may not be recognized without targeted assessment.
Clinical manifestations
Skin disease
The characteristic rash consists of red, ring-shaped or polycyclic patches, sometimes with scaling. Lesions commonly involve the face, scalp, and areas around the eyes, but may occur elsewhere. Their appearance resembles subacute cutaneous lupus erythematosus.
The eruption may be present at birth or develop during the first weeks or months of life. Ultraviolet exposure can provoke or accentuate it. Most lesions resolve within approximately six to eight months as maternal antibodies disappear. Temporary changes in pigmentation may persist longer; persistent small dilated blood vessels and, less commonly, scarring can occur.
Cardiac disease
Congenital heart block is the most important potentially permanent manifestation. It usually develops during mid-pregnancy, particularly around 18–24 weeks, although recognition can occur later.
Heart block may be incomplete or complete. In complete atrioventricular block, impulses from the atria no longer conduct normally to the ventricles, producing a slow ventricular rhythm. Severe cases may cause fetal fluid accumulation, heart failure, or death.
Cardiac involvement can also include injury to heart muscle and endocardial fibroelastosis, a thickening of the heart’s inner lining. Cardiac and skin disease may occur together or independently.
Blood and liver abnormalities
Possible blood abnormalities include anemia, reduced platelet counts, and neutropenia. Liver involvement may produce elevated liver enzymes, enlargement of the liver, or cholestasis, in which bile flow is impaired.
These manifestations are usually transient. Severe hepatic or hematologic disease is less common.
Diagnosis
Diagnosis combines characteristic fetal or infant findings with evidence of relevant maternal antibodies. Because mothers may be asymptomatic, an affected infant can be the first indication of maternal autoimmunity.
Evaluation may include:
- Testing maternal or infant blood for anti-Ro/SSA and anti-La/SSB antibodies.
- Electrocardiography to identify conduction abnormalities.
- Fetal or postnatal echocardiography to assess rhythm, heart function, and structural findings.
- A complete blood count and liver biochemical tests.
- Skin biopsy when the appearance of an eruption is atypical or the diagnosis remains uncertain.
Antibodies detected in an infant during early life may be maternally derived; their presence does not by itself establish that the child has an ongoing autoimmune disease. The differential diagnosis includes other causes of infantile annular eruptions and congenital heart block unrelated to maternal autoantibodies.
Management and outcomes
Management depends on the organs involved. Cutaneous disease is generally managed with photoprotection and, when needed, topical corticosteroids. Blood and liver abnormalities are followed according to their severity and commonly resolve without lasting impairment.
Complete heart block generally does not reverse when maternal antibodies disappear. Many affected children require a permanent pacemaker, and cardiac follow-up remains important because ventricular dysfunction can develop or persist.
For antibody-positive pregnancies, specialist care may include fetal rhythm and cardiac-function surveillance. The optimal surveillance schedule and the ability of monitoring to prevent complete block remain uncertain, partly because conduction disease can progress rapidly.
Hydroxychloroquine use during pregnancy has evidence supporting a reduction in recurrent cardiac neonatal lupus in women with a previously affected pregnancy, but it does not eliminate the risk. Evidence for prenatal corticosteroids, intravenous immunoglobulin, and other interventions varies by clinical setting. Established complete heart block is generally irreversible, and no prenatal therapy reliably restores normal conduction.
Most infants with exclusively noncardiac disease have resolution as maternal antibodies are cleared. Neonatal lupus does not mean that the child will necessarily develop systemic lupus erythematosus later in life.